Table 1 Quality description of the included studies according to the criteria of study population (inception cohort, description of source population, description of inclusion/exclusion criteria), follow-up Blebbistatin price (at least 12 months, drop outs, description of completers and drop outs, design of the study), treatment (standardized), prognostic factors (relevant, valid, presented), outcome (relevant, valid, presented), analysis
(univariate, multivariate), and the quality score (good ≥ 13, 9 ≤ moderate ≤ 12) (See also “”Appendix B”" for definitions) Primary author year of publication Study population Follow-up Treatment Prognostic factors Outcome Analysis Quality Incept Pop Incl Year %Out Descrp Dsgn Stnd Rlvnt Valid Pres Rlvnt Valid Pres Uni Multi Sum Good quality Gross et al. (2004) 0 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 13 Gross and Battié (2004) 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 14 Gross and Battié (2005) 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 14 Gross and Battié (2006) 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 14 Streibelt et al. (2009) 0 1 1 1 0 0 1 1 1 1 https://www.selleckchem.com/products/bb-94.html 1 1 1 1 1 1 13 Moderate quality Bachman et al. 2003) 0 1 1 1 1 0 1 1 1 1 1 1 1 1 0 0 12 Branton et al. (2010) 0 1 1 1 1 1 1 0 1 1 0 1 1 0 1 1 12 Cheng and Cheng (2010) 0 1 1 0 1 0 1 0 1 1 1 1 1 1 1 1 12 Fishbain et al. (1999) 0 1 1 1 0 0 1 1 1 1 1 1 1 1 0 0 11 Gouttebarge et al. (2009a) 1 1 1 1 1 1 1 0
0 0 0 1 1 1 1 0 11 Gross et al. (2006) 0 1 1 1 0 0 1 0 0 0 0 1 1 1 1 1 9 Hazard et al. (1991) 0 1 1 1 0 1 1 1 1 1 1 1 1 1 0 0 12 Kool et al. (2008)
0 1 1 0 1 1 1 1 0 0 0 1 1 1 0 0 9 Matheson et al. (2002) 0 1 1 0 1 0 1 0 1 1 0 1 1 1 1 1 11 Mayer et al. (1986) 0 1 0 0 1 0 1 1 1 1 1 1 1 1 0 0 10 Strand et al. (2001) 0 1 1 1 0 0 1 1 1 1 1 1 1 1 1 0 12 Vowles et al. (2004) 0 0 1 0 1 0 1 1 1 1 1 1 1 1 0 0 10 Sum score 1 17 17 13 12 8 18 9 15 15 13 18 18 17 11 9 Characteristics of the studies The 18 studies reported on 4,113 participants (median = 147, IQR = 152, range 30–650) (Table 2). Ten studies reported on patients with low back pain, six studies Aspartate in patients with musculoskeletal https://www.selleckchem.com/products/kpt-8602.html disorders (MSDs) in general, and in one study on patients with upper extremity disorders. In one study, the type or region of the MSDs was not specified.